Your browser doesn't support javascript.
loading
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang, Qi; Riley-Gillis, Bridget; Han, Lina; Jia, Yannan; Lodi, Alessia; Zhang, Haijiao; Ganesan, Saravanan; Pan, Rongqing; Konoplev, Sergej N; Sweeney, Shannon R; Ryan, Jeremy A; Jitkova, Yulia; Dunner, Kenneth; Grosskurth, Shaun E; Vijay, Priyanka; Ghosh, Sujana; Lu, Charles; Ma, Wencai; Kurtz, Stephen; Ruvolo, Vivian R; Ma, Helen; Weng, Connie C; Ramage, Cassandra L; Baran, Natalia; Shi, Ce; Cai, Tianyu; Davis, Richard Eric; Battula, Venkata L; Mi, Yingchang; Wang, Jing; DiNardo, Courtney D; Andreeff, Michael; Tyner, Jeffery W; Schimmer, Aaron; Letai, Anthony; Padua, Rose Ann; Bueso-Ramos, Carlos E; Tiziani, Stefano; Leverson, Joel; Popovic, Relja; Konopleva, Marina.
Afiliación
  • Zhang Q; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Riley-Gillis B; AbbVie Inc., North Chicago, IL, USA.
  • Han L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jia Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lodi A; Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Zhang H; Department of Nutritional Sciences, Department of Pediatrics, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, 78712, USA.
  • Ganesan S; Department of Cell, Developmental & Cancer Biology, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Pan R; Université de Paris, Institut de la Recherche Saint-Louis (IRSL), Inserm Unit 1131, Paris, France.
  • Konoplev SN; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sweeney SR; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ryan JA; Department of Nutritional Sciences, Department of Pediatrics, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, 78712, USA.
  • Jitkova Y; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Dunner K; Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Grosskurth SE; High Resolution Electron Microscopy Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vijay P; AbbVie Inc., North Chicago, IL, USA.
  • Ghosh S; AbbVie Inc., North Chicago, IL, USA.
  • Lu C; AbbVie Inc., North Chicago, IL, USA.
  • Ma W; AbbVie Inc., North Chicago, IL, USA.
  • Kurtz S; Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ruvolo VR; Department of Cell, Developmental & Cancer Biology, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Ma H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Weng CC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ramage CL; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Baran N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shi C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cai T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davis RE; Department of Hematology, The First Hospital Affiliated Harbin Medical University, Harbin, China.
  • Battula VL; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mi Y; Department of Lymphoma & Myeloma Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • DiNardo CD; Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Andreeff M; Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tyner JW; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Schimmer A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Letai A; Department of Cell, Developmental & Cancer Biology, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Padua RA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bueso-Ramos CE; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tiziani S; Université de Paris, Institut de la Recherche Saint-Louis (IRSL), Inserm Unit 1131, Paris, France.
  • Leverson J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Popovic R; Department of Nutritional Sciences, Department of Pediatrics, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, 78712, USA.
  • Konopleva M; AbbVie Inc., North Chicago, IL, USA.
Signal Transduct Target Ther ; 7(1): 110, 2022 Apr 01.
Article en En | MEDLINE | ID: mdl-35365596
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Signal Transduct Target Ther Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Signal Transduct Target Ther Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido